Archive for May, 2013

Association for Molecular Pathology v Myriad: Attorneys React

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. While the dust has settled on the oral hearings of Association for Molecular Pathology (AMP) v Myriad (read our report […]


Drug Patent Expirations for May 7 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for May 7 2013

Tradename Applicant Generic Name Patent
Expiration
GEMZAR

Lilly

gemcitabine hydrochloride

May 7, 2013
HUMALOG

Lilly

insulin lispro recombinant

May 7, 2013
HUMALOG
KWIKPEN

Lilly

insulin lispro recombinant

May 7, 2013
HUMALOG MIX 50/50

Lilly

insulin lispro protamine recombinant; insulin lispro
recombinant

May 7,
2013
HUMALOG MIX 50/50 KWIKPEN

Lilly

insulin lispro protamine recombinant; insulin lispro
recombinant

May 7,
2013
HUMALOG MIX 75/25

Lilly

insulin lispro protamine recombinant; insulin lispro
recombinant

May 7,
2013
HUMALOG MIX 75/25 KWIKPEN

Lilly

insulin lispro protamine recombinant; insulin lispro
recombinant

May 7,
2013
HUMALOG
PEN

Lilly

insulin lispro recombinant

May 7, 2013
PREVACID

Takeda
Pharms Usa

lansoprazole

May 7, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Which pharmaceutical companies have the most drugs

Which Companies Have the Most Branded
Drugs?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Strategies for improving communication between scientists and the public

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Strategies for improving communication between scientists and the public
Go to paperABSTRACT: It is believed that a scientifically literate society benefit…


Singapore’s biomedical science sector development strategy: Is it sustainable?

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Singapore’s biomedical science sector development strategy: Is it sustainable?
Go to paperABSTRACT: This paper outlines the strategic efforts undertaken by…


Drug Patent Expirations for Apr 30 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for April 30 2013

Tradename Applicant Generic Name Patent
Expiration
ALVESCO

Takeda
Gmbh

ciclesonide

Apr 30, 2013
CEDAX

Pernix
Therap

ceftibuten
dihydrate

Apr 30,
2013
ZETONNA

Takeda
Gmbh

ciclesonide

Apr 30, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Top<br />
selling drugs

What are the Top-selling
Drugs?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Introducing BiologicPatentWatch: Biotechnology Industry Competitive Intelligence

After months of development, BiologicPatentWatch.com is live. Building on the framework of DrugPatentWatch, BiologicPatentWatch provides comprehensive details on FDA approved biologic drugs, developers and patents. The integrated databases allow both freeform searching and dynamic browsing, making it easy to find information on drug patents both in the US and internationally, Orphan Drug Status, trends in […]


Bowman v. Monsanto Supreme Court Decision for GM Seeds Patents, Licensing

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In an unanimous decision in Bowman v. Monsanto, argued February 19, 2013 and decided May 13, 2013, the U.S. Supreme Court explicitly confirms that the exhaustion doctrine does not […]


Drug Patent Expirations for Apr 29 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

DrugPatentWatch -- sales, statistics, drug application information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for April 29 2013

Tradename Applicant Generic Name Patent
Expiration
HYTRIN

Abbott

terazosin
hydrochloride

Apr 29,
2013

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Future drug patent expirations by month

How Many Drug Patents Will Expire in the Coming
Months?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for Apr 26 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

BiologicPatentWatch -- biologic drug patent expiration information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for April 26 2013

Tradename Applicant Generic Name Patent
Expiration
ZELNORM

Novartis

tegaserod
maleate

Apr 26,
2013

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Which pharma companies have the most drug patents

Which Companies Have the Most Active Drug
Patents?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.